scholarly journals Baseline Predictors of A1C Reduction in Adults Using Sensor-Augmented Pump Therapy or Multiple Daily Injection Therapy: The STAR 3 Experience

2011 ◽  
Vol 13 (6) ◽  
pp. 601-606 ◽  
Author(s):  
John B. Buse ◽  
George Dailey ◽  
Andrew A. Ahmann ◽  
Richard M. Bergenstal ◽  
Jennifer B. Green ◽  
...  
2012 ◽  
Vol 15 (4) ◽  
pp. 46-60
Author(s):  
Tatiana Evgen'evna Taranushenko ◽  
Viktoriya Nikolaevna Panfilova ◽  
Oksana Alekseevna Terent'eva ◽  
Nadezhda Dmitrievna Koreshkova ◽  
Maria Nikolaevna Petrova

Aim. To summarize practical experience of insulin pump therapy (IPT) in child population of Krasnoyarsk and to assess its efficacy for treatment of type 1 diabetes mellitus (T1DM) in paediatrics. Materials and Methods. We performed a comparative analysis of clinical and laboratory data from 48 children with T1DM prior to and after 6-12 months of IPT. Results. IPT yielded fourfold decrease in complaints of hyperglycemia and labile glycemia without concurrent increase in reports of severe hypoglycemia.  We observed a trend for lowering of mean HbA1c levels, where 65% of patients showed positive dynamics in comparison with the period of multiple daily injection regimen. Interestingly, after 6-12 months of IPT, insulin requirement dropped in most patients. Conclusion. Our data support clinical efficiency and safety of IPT, as well as superiority of this treatment over multiple daily injection regimen. We conclude that IPT is a treatment of choice for children with T1DM.


2021 ◽  
pp. 193229682110626
Author(s):  
David T Ahn

Although automated bolus calculators (ABCs) have become a mainstay in insulin pump therapy, they have not achieved similar levels of adoption by persons with diabetes (PWD) using multiple daily injections of insulin (MDI). Only a small number of blood glucose meters (BGMs) have incorporated ABC functionality and the proliferation of unregulated ABC smartphone apps raised safety concerns and eventually led to Food and Drug Administration (FDA)–mandated regulatory oversight for these types of apps. With the recent introduction of smartphone-connected insulin pens, manufacturer-supported companion ABC apps may offer an ideal solution for PWD and health care professionals that reduces errors of mental math when calculating bolus insulin dosing, increases the quality of diabetes data reporting, and improves glycemic outcomes.


Diabetes Care ◽  
1983 ◽  
Vol 6 (3) ◽  
pp. 241-244 ◽  
Author(s):  
M. Grinvalsky ◽  
D. M. Nathan

Sign in / Sign up

Export Citation Format

Share Document